Wegovy, hepatitis and the liver: what the 2026 approval actually covers

The biggest misconception: "Wegovy treats hepatitis" is both true and misleading

Most people searching this topic have one of two things in mind. Either they have read the July 2026 news about Wegovy being approved for liver disease and want to understand it, or they have a hepatitis diagnosis and are wondering whether semaglutide might help them. Both are fair questions. The confusion lies in the word "hepatitis" itself, which simply means inflammation of the liver and covers a wide range of causes.

Viral hepatitis, caused by the hepatitis A, B or C viruses, is a distinct infectious disease. Wegovy has no licensed indication for viral hepatitis, and the clinical trials that led to the July 2026 approval did not involve patients with viral hepatitis. Making this distinction clearly is important, because assuming the two are interchangeable could lead someone to either overlook a medicine that might genuinely help their condition, or to pursue one that is not appropriate for what they actually have.

The condition Wegovy is now conditionally approved for, MASH, shares nothing with viral hepatitis except that both involve liver inflammation. MASH develops when fat accumulates in liver tissue and triggers an inflammatory response, gradually causing fibrosis (scarring). It is closely linked to obesity, type 2 diabetes and metabolic syndrome. Understanding that distinction is the starting point for everything else on this page. The full semaglutide overview covers the medicine's broader mechanisms if you want more background on how it works.

What the MASH indication involves, and why semaglutide may help

MASH, formerly called NASH (non-alcoholic steatohepatitis), is now recognised as one of the more serious consequences of metabolic disease. In its advanced stages it can progress to cirrhosis and liver failure. The challenge has always been that few treatments exist beyond sustained weight loss and lifestyle change.

Semaglutide's approval for MASH makes biological sense. By reducing appetite and slowing gastric emptying, the medicine promotes meaningful weight loss, and liver fat is often the first fat depot to reduce when body weight falls. Reduced liver fat means less inflammation, which in turn slows fibrosis. The MHRA's conditional approval specifically targets adults with moderate-to-advanced fibrosis, reflecting where the trial evidence was strongest. The MHRA announcement of 3 July 2026 sets out the scope of this approval clearly.

It is worth being precise about what "conditional approval" means. The MHRA can grant approval on the basis of promising trial data while requiring the manufacturer to submit further evidence confirming long-term outcomes. So the approval is real and current, but the evidence base will continue to grow. Clinicians prescribing for MASH will be working within specialist hepatology or metabolic medicine services, not via a weight-management route. If you are managing a liver condition alongside weight concerns, you may find our page on semaglutide and gallbladder conditions relevant too, since biliary issues and liver disease often share metabolic roots.

Wegovy for weight management: what remains unchanged for most patients

The MASH approval does not alter the weight-management licence that most Wegovy patients are using. For weight loss, semaglutide remains licensed for adults with a BMI of 30 or above, or 27–29.9 with at least one weight-related condition such as high blood pressure, raised cholesterol or obstructive sleep apnoea. The dosing schedule begins at 0.25mg weekly and titrates upward under prescriber guidance, with 2.4mg as the established maintenance dose and 7.2mg as the newer higher maintenance option approved by the MHRA in April 2026.

People taking Wegovy for weight management should be aware that the medicine does affect the digestive system broadly, which occasionally raises questions about other GI conditions. Our pages on Wegovy and gastritis and Wegovy and ulcerative colitis address some of those concerns in detail. The NHS patient-level guidance on semaglutide is the most straightforward reference for common side effects and storage: the NHS semaglutide medicines page is worth bookmarking alongside your Patient Information Leaflet.

For those thinking about cost alongside these questions, our Wegovy cost guide sets out what a legitimate private prescription actually includes. A quick note on timing: orders placed before noon on a weekday are reviewed the same day by a named prescriber, dispatched that afternoon, and arrive the next working day. That rhythm suits a lot of people who need things to fit around work or school-day commitments.

If you have liver disease and are wondering whether semaglutide could be part of your treatment, that conversation belongs with a specialist who knows your case. A weight-management prescriber can assess the weight side of things, but a hepatologist should be involved where MASH or significant fibrosis is present. Our patient guide to Wegovy covers the broader questions people ask before starting. For anything outside weight management, speak to your GP first.